{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:02:31Z","timestamp":1781222551924,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.pharma.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T16:22:50Z","timestamp":1771086170000},"page":"726-735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mise en place du marquage du [68Ga]Ga-FAPI-46\u00a0dans le cadre de l\u2019essai clinique PRECISION"],"prefix":"10.1016","volume":"84","author":[{"given":"No\u00e9mie","family":"Allouche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Coussirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tonnelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Clatot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8972-9022","authenticated-orcid":false,"given":"Pierre","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2026.02.004_bib0140","series-title":"Panorama des cancers en France\u00a0\u2013\u00a0\u00e9dition 2024","year":"2024"},{"issue":"7","key":"10.1016\/j.pharma.2026.02.004_bib0145","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bulcan.2025.02.014","article-title":"Imagerie mol\u00e9culaire et radio-ligands dans le cancer du sein","volume":"112","author":"Masse","year":"2025","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.pharma.2026.02.004_bib0150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bulcan.2019.01.002","article-title":"Actualisation des recommandations de bonne pratique clinique pour l\u2019utilisation de la TEP en canc\u00e9rologie","volume":"106","author":"Sala\u00fcn","year":"2019","journal-title":"Bull Cancer"},{"key":"10.1016\/j.pharma.2026.02.004_bib0155","doi-asserted-by":"crossref","first-page":"1358070","DOI":"10.3389\/fonc.2024.1358070","article-title":"Applications of FAPI PET\/CT in the diagnosis and treatment of breast and the most common gynecologic malignancies: a literature review","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.pharma.2026.02.004_bib0160","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2967\/jnumed.122.264871","article-title":"Initial results of 68Ga-FAPI-46 PET\/MRI to assess response to neoadjuvant chemotherapy in breast cancer","volume":"64","author":"Backhaus","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharma.2026.02.004_bib0165","doi-asserted-by":"crossref","first-page":"101417","DOI":"10.1016\/j.smim.2020.101417","article-title":"Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies","volume":"48","author":"Mhaidly","year":"2020","journal-title":"Semin Immunol"},{"issue":"5\u20136","key":"10.1016\/j.pharma.2026.02.004_bib0170","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics Clin Appl"},{"issue":"5","key":"10.1016\/j.pharma.2026.02.004_bib0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of fibroblast activation protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"10.1016\/j.pharma.2026.02.004_bib0180","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.7150\/thno.69475","article-title":"Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.pharma.2026.02.004_bib0185","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.pharma.2026.02.004_bib0190","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1248\/cpb.c24-00531","article-title":"GMP-compliant automated radiolabeling and quality controls of [68Ga]Ga-FAPI-46 for fibroblast activation protein-targeted PET imaging in clinical settings","volume":"72","author":"Rubira","year":"2024","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.pharma.2026.02.004_bib0195","series-title":"Bonnes pratiques de pr\u00e9paration \u00e9dition 2023","year":"2023"},{"key":"10.1016\/j.pharma.2026.02.004_bib0200","doi-asserted-by":"crossref","first-page":"111211","DOI":"10.1016\/j.apradiso.2024.111211","article-title":"[68Ga]Ga-FAPI-46 synthesis on a GAIA\u00ae module system: thorough study of the automated radiolabeling reaction conditions","volume":"206","author":"Rubira","year":"2024","journal-title":"Appl Radiat Isot"},{"issue":"8","key":"10.1016\/j.pharma.2026.02.004_bib0205","doi-asserted-by":"crossref","first-page":"e0134965","DOI":"10.1371\/journal.pone.0134965","article-title":"Cancer associated fibroblasts in stage I-IIIA NSCLC: prognostic impact and their correlations with tumor molecular markers","volume":"10","author":"Kilvaer","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharma.2026.02.004_bib0210","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/molecules27030675","article-title":"New fully automated preparation of high apparent molar activity 68Ga-FAPI-46 on a Trasis AiO Platform","volume":"27","author":"Da Pieve","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.pharma.2026.02.004_bib0215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s41181-022-00172-1","article-title":"Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types","volume":"7","author":"Alfteimi","year":"2022","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.pharma.2026.02.004_bib0220","series-title":"Le [68Ga]Ga-FAPI-46\u00a0: un traceur TEP prometteur pour les maladies inflammatoires et fibrosantes\u00a0: production au sein de la radiopharmacie de Brest","first-page":"66","author":"Grassal","year":"2023"},{"issue":"8","key":"10.1016\/j.pharma.2026.02.004_bib0225","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/ph16081138","article-title":"Automated synthesis of [68Ga]Ga-FAPI-46 on a scintomics GRP synthesizer","volume":"16","author":"Plhak","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.pharma.2026.02.004_bib0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41181-020-00112-x","article-title":"Fully-automated production of [68Ga]Ga-FAPI-46 for clinical application","volume":"5","author":"Spreckelmeyer","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"10","key":"10.1016\/j.pharma.2026.02.004_bib0235","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.pharma.2026.02.004_bib0240","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ph18101475","article-title":"Production and quality control of [68Ga]Ga-FAPI-46: development of an investigational medicinal product dossier for a bicentric clinical trial","volume":"18","author":"Cafaro","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.pharma.2026.02.004_bib0245","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.semnuclmed.2025.02.011","article-title":"FAPI PET in the management of lung tumors","volume":"55","author":"Deleu","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"2","key":"10.1016\/j.pharma.2026.02.004_bib0250","first-page":"123","article-title":"Diagnostic value of 18F-FDG PET\/CT and 68Ga-FAPI PET\/CT in primary liver cancer: a systematic review and meta-analysis","volume":"26","author":"Jiao","year":"2023","journal-title":"Hell J Nucl Med"},{"issue":"5","key":"10.1016\/j.pharma.2026.02.004_bib0255","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.semnuclmed.2025.06.011","article-title":"The value of FAPI PET\/CT in cholangiocarcinoma and pancreatic cancer: an update","volume":"55","author":"Pabst","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"2","key":"10.1016\/j.pharma.2026.02.004_bib0260","doi-asserted-by":"crossref","first-page":"e220749","DOI":"10.1148\/radiol.220749","article-title":"FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.pharma.2026.02.004_bib0265","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/s00256-024-04834-w","article-title":"Recent advances in nuclear medicine and their role in inflammatory arthritis: focus on the emerging role of FAPI PET\/CT","volume":"54","author":"Schmidkonz","year":"2025","journal-title":"Skeletal Radiol"},{"issue":"4","key":"10.1016\/j.pharma.2026.02.004_bib0135","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/biomedicines13040775","article-title":"FAPi PET\/CT imaging to identify fibrosis in immune-mediated inflammatory diseases","volume":"13","author":"Lartey","year":"2025","journal-title":"Biomedicines"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:20:14Z","timestamp":1781220014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003450926000295"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.02.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mise en place du marquage du [68Ga]Ga-FAPI-46\u00a0dans le cadre de l\u2019essai clinique PRECISION","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}